Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses
OPEN BMJ (Clinical research ed.) | 7 Feb 2020
JD Wallach, K Wang, AD Zhang, D Cheng, HK Grossetta Nardini, H Lin, MB Bracken, M Desai, HM Krumholz and JS Ross
To conduct a systematic review and meta-analysis of the effects of rosiglitazone treatment on cardiovascular risk and mortality using multiple data sources and varying analytical approaches with three aims in mind: to clarify uncertainties about the cardiovascular risk of rosiglitazone; to determine whether different analytical approaches are likely to alter the conclusions of adverse event meta-analyses; and to inform efforts to promote clinical trial transparency and data sharing.
* Data courtesy of Altmetric.com